HC Wainwright & Co. Maintains Buy on Biogen, Raises Price Target to $251
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Andrew S. Fein maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $237 to $251.
HC Wainwright & Co. analyst Andrew S. Fein maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $237 to $251.